Rosiglitazone pretreatment protects against lipopolysaccharide-induced fetal demise through inhibiting placental inflammation. (5th March 2016)
- Record Type:
- Journal Article
- Title:
- Rosiglitazone pretreatment protects against lipopolysaccharide-induced fetal demise through inhibiting placental inflammation. (5th March 2016)
- Main Title:
- Rosiglitazone pretreatment protects against lipopolysaccharide-induced fetal demise through inhibiting placental inflammation
- Authors:
- Bo, Qing-Li
Chen, Yuan-Hua
Yu, Zhen
Fu, Lin
Zhou, Yan
Zhang, Gui-Bin
Wang, Hua
Zhang, Zhi-Hui
Xu, De-Xiang - Abstract:
- Abstract: Peroxisome proliferator-activated receptor (PPAR)-γ is highly expressed in human and rodent placentas. Nevertheless, its function remains obscure. The present study investigated the effects of rosiglitazone, a PPAR-γ agonist, on LPS-induced fetal death. All pregnant mice except controls were intraperitoneally injected with LPS (150 μg/kg) daily from gestational day (GD)15 to GD17. As expected, maternal LPS injection caused placental inflammation and resulted in 63.6% fetal death in dams that completed the pregnancy. Interestingly, LPS-induced fetal mortality was reduced to 16.0% when pregnant mice were pretreated with RSG. Additional experiment showed that rosiglitazone pretreatment inhibited LPS-induced expressions of tumor necrosis factor ( Tnf )- α, interleukin ( Il )- 1β, Il-6, macrophage inflammatory protein ( Mip )- 2 and keratinocyte-derived chemokine ( Kc ) in mouse placenta. Although rosiglitazone had little effect on LPS-evoked elevation of IL-10 in amniotic fluid, it alleviated LPS-evoked release of TNF-α and MIP-2 in amniotic fluid. Further analysis showed that pretreatment with rosiglitazone, which activated placental PPAR-γ signaling, simultaneously suppressed LPS-evoked nuclear factor kappa B (NF-κB) activation and blocked nuclear translocation of NF-κB p65 and p50 subunits in trophoblast giant cells of the labyrinth layer. These results provide a mechanistic explanation for PPAR-γ-mediated anti-inflammatory activity in the placentas. Overall, theAbstract: Peroxisome proliferator-activated receptor (PPAR)-γ is highly expressed in human and rodent placentas. Nevertheless, its function remains obscure. The present study investigated the effects of rosiglitazone, a PPAR-γ agonist, on LPS-induced fetal death. All pregnant mice except controls were intraperitoneally injected with LPS (150 μg/kg) daily from gestational day (GD)15 to GD17. As expected, maternal LPS injection caused placental inflammation and resulted in 63.6% fetal death in dams that completed the pregnancy. Interestingly, LPS-induced fetal mortality was reduced to 16.0% when pregnant mice were pretreated with RSG. Additional experiment showed that rosiglitazone pretreatment inhibited LPS-induced expressions of tumor necrosis factor ( Tnf )- α, interleukin ( Il )- 1β, Il-6, macrophage inflammatory protein ( Mip )- 2 and keratinocyte-derived chemokine ( Kc ) in mouse placenta. Although rosiglitazone had little effect on LPS-evoked elevation of IL-10 in amniotic fluid, it alleviated LPS-evoked release of TNF-α and MIP-2 in amniotic fluid. Further analysis showed that pretreatment with rosiglitazone, which activated placental PPAR-γ signaling, simultaneously suppressed LPS-evoked nuclear factor kappa B (NF-κB) activation and blocked nuclear translocation of NF-κB p65 and p50 subunits in trophoblast giant cells of the labyrinth layer. These results provide a mechanistic explanation for PPAR-γ-mediated anti-inflammatory activity in the placentas. Overall, the present study provides additional evidence for roles of PPAR-γ as an important regulator of placental inflammation. Highlights: RSG pretreatment alleviates LPS-induced fetal death in mice. RSG activates PPAR-γ signaling in mouse placenta. RSG pretreatment inhibits LPS-evoked placental NF-κB activation. RSG blocks LPS-induced nuclear translocation of placental NF-κB p65 and p50 subunits. RSG inhibits LPS-induced placental inflammation through activating PPAR-γ signaling. … (more)
- Is Part Of:
- Molecular and cellular endocrinology. Volume 423(2016)
- Journal:
- Molecular and cellular endocrinology
- Issue:
- Volume 423(2016)
- Issue Display:
- Volume 423, Issue 2016 (2016)
- Year:
- 2016
- Volume:
- 423
- Issue:
- 2016
- Issue Sort Value:
- 2016-0423-2016-0000
- Page Start:
- 51
- Page End:
- 59
- Publication Date:
- 2016-03-05
- Subjects:
- Rosiglitazone -- Peroxisome proliferator-activated receptor-γ -- Lipopolysaccharide -- Inflammation -- Fetal death
Endocrinology -- Periodicals
Molecular biology -- Periodicals
Cytology -- Periodicals
Endocrinology -- Periodicals
Hormones -- Periodicals
Endocrinologie -- Périodiques
Cytology
Endocrinology
Molecular biology
Periodicals
573.4 - Journal URLs:
- http://www.sciencedirect.com/science/journal/03037207 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.mce.2016.01.004 ↗
- Languages:
- English
- ISSNs:
- 0303-7207
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5900.760000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 1277.xml